Cargando…

Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab

Vascular endothelial growth factor (VEGF) inhibitors have been widely investigated in the last 10 years, with particular attention paid to their adverse effects because of their efficacy in improving cancer patient survival. Previous research primarily focused on the monoclonal anti‐vascular endothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Guo‐Yu, Cheng, Wen‐Chien, Tu, Chih‐Yen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715838/
https://www.ncbi.nlm.nih.gov/pubmed/36305200
http://dx.doi.org/10.1111/1759-7714.14701
_version_ 1784842546777686016
author Chen, Guo‐Yu
Cheng, Wen‐Chien
Tu, Chih‐Yen
author_facet Chen, Guo‐Yu
Cheng, Wen‐Chien
Tu, Chih‐Yen
author_sort Chen, Guo‐Yu
collection PubMed
description Vascular endothelial growth factor (VEGF) inhibitors have been widely investigated in the last 10 years, with particular attention paid to their adverse effects because of their efficacy in improving cancer patient survival. Previous research primarily focused on the monoclonal anti‐vascular endothelial growth factor antibody bevacizumab and its adverse outcomes. Reports show a higher risk of ischemic stroke, one of the most concerning clinically relevant events, after treatment with bevacizumab. However, few studies have examined the relationship between anti‐VEGF receptor 2 monoclonal antibody ramucirumab and its adverse events. This article presents the case of a non–small‐cell lung cancer patient who experienced a new ischemic stroke after treatment with ramucirumab. The findings suggest that further studies may be necessary to investigate the relationship between ramucirumab and the risk of ischemic stroke.
format Online
Article
Text
id pubmed-9715838
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-97158382022-12-05 Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab Chen, Guo‐Yu Cheng, Wen‐Chien Tu, Chih‐Yen Thorac Cancer Case Reports Vascular endothelial growth factor (VEGF) inhibitors have been widely investigated in the last 10 years, with particular attention paid to their adverse effects because of their efficacy in improving cancer patient survival. Previous research primarily focused on the monoclonal anti‐vascular endothelial growth factor antibody bevacizumab and its adverse outcomes. Reports show a higher risk of ischemic stroke, one of the most concerning clinically relevant events, after treatment with bevacizumab. However, few studies have examined the relationship between anti‐VEGF receptor 2 monoclonal antibody ramucirumab and its adverse events. This article presents the case of a non–small‐cell lung cancer patient who experienced a new ischemic stroke after treatment with ramucirumab. The findings suggest that further studies may be necessary to investigate the relationship between ramucirumab and the risk of ischemic stroke. John Wiley & Sons Australia, Ltd 2022-10-28 2022-12 /pmc/articles/PMC9715838/ /pubmed/36305200 http://dx.doi.org/10.1111/1759-7714.14701 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Chen, Guo‐Yu
Cheng, Wen‐Chien
Tu, Chih‐Yen
Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab
title Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab
title_full Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab
title_fullStr Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab
title_full_unstemmed Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab
title_short Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab
title_sort ischemic stroke in a patient with egfr‐mutated non–small‐cell lung cancer after treatment with ramucirumab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715838/
https://www.ncbi.nlm.nih.gov/pubmed/36305200
http://dx.doi.org/10.1111/1759-7714.14701
work_keys_str_mv AT chenguoyu ischemicstrokeinapatientwithegfrmutatednonsmallcelllungcanceraftertreatmentwithramucirumab
AT chengwenchien ischemicstrokeinapatientwithegfrmutatednonsmallcelllungcanceraftertreatmentwithramucirumab
AT tuchihyen ischemicstrokeinapatientwithegfrmutatednonsmallcelllungcanceraftertreatmentwithramucirumab